Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Dr. Jennifer Brown on Ibrutinib and Idelalisib for CLL

April 17th 2013

Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses the treatment of chronic lymphocytic leukemia with ibrutinib, idelalisib, and other agents.

Ibrutinib Receives Additional Breakthrough Designation for CLL

April 8th 2013

After receiving breakthrough therapy designation from the FDA for the treatment of two B-cell malignancies earlier this year, ibrutinib has received an additional breakthrough designation.

Seeking a Standard in the Treatment of Elderly Patients With CLL

March 28th 2013

While there is no standard treatment for most patients with chronic lymphocytic leukemia who are age 65 years and older, several regimens are being tested in clinical trials.

BCR Inhibitors Show Promise in Treating Chronic Lymphocytic Leukemia

March 25th 2013

Two novel, oral drugs that target the B-Cell receptor signal transduction pathway could significantly change the way chronic lymphocytic leukemia is treated.

Dr. Jennifer Brown on Gauging Response in CLL

February 20th 2013

Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses gauging response in chronic lymphocytic leukemia.

Biotech Focus: Tracking the Oncology Pipeline

February 13th 2013

Several updates highlighted at the 2012 American Society of Hematology Annual Meeting as well as other developments.

Obinutuzumab Significantly Improves PFS in CLL

January 31st 2013

The first set of results from a phase III clinical trial found that obinutuzumab plus chlorambucil chemotherapy significantly improved PFS in patients with CLL.

Study Suggests Patient Age Should Factor Into CLL Treatment Selection

January 30th 2013

Research from the Ohio State University Comprehensive Cancer Center suggests that chlorambucil may be better than fludarabine in treating older patients with CLL, and that rituximab is beneficial regardless of age.

Dr. Furman on Trials Examining Ibrutinib's Safety in CLL

January 18th 2013

Richard R. Furman, MD, from the Weill Cornell Medical Center, discusses the safety profile of the oral BTK inhibitor ibrutinib in both relapsed/refractory and treatment naive patients with chronic lymphocytic leukemia.

Dr. John Byrd Discusses Ibrutinib in CLL

December 8th 2012

John C. Byrd, MD, director of the division of hematology at The Ohio State University Comprehensive Cancer Center, discusses the new and updated results of a phase Ib/II study involving ibrutinib at the ASH Annual Meeting and Exposition.

Small-Molecule Inhibitors Hold Promise for Elderly CLL Patients

October 29th 2012

In early clinical trials, small-molecule inhibitors have demonstrated improvement in response rates in elderly patients with chronic lymphocytic leukemia.

Dr. Zelenetz Previews the 2012 ASH Annual Meeting

September 26th 2012

Andrew D. Zelenetz, MD, PhD, from Memorial Sloan-Kettering Cancer Center, previews several trials that will likely be presented at the 54th annual ASH meeting.

Emerging Markers Point to Future Strategies in CLL: An Interview With William G. Wierda, MD, PhD

April 27th 2012

William G. Wierda, MD, PhD, discussed the management of chronic lymphocytic leukemia at the 16th Annual International Congress on Hematologic Malignancies.

Novel Treatments for Chronic Lymphocytic Leukemia

April 20th 2012

Results of recent trials investigating novel therapies for chronic lymphocytic leukemia were discussed at the 16th Annual International Congress on Hematologic Malignancies.

Dr. Wierda Discusses Watchful Waiting in CLL

March 14th 2012

Dr. William Wierda, from the MD Anderson Cancer Center, Discusses Watchful Waiting in CLL

Dr. William Wierda Discusses Diagnosing CLL

March 5th 2012

Dr. William Wierda, from MD Anderson Cancer Center, on Diagnosing Chronic Lymphocytic Leukemia

New Model Helps Guide Treatment Options in CLL

February 27th 2012

A number of prognostic factors can help identify those at a high risk for CLL progression who may benefit from early intervention.

Dr. O'Brien Discusses the Standard of Care for CLL

January 22nd 2012

Dr. Susan O'Brien, from the MD Anderson Cancer Center, Discusses the Standard of Care for CLL

FISH Testing Guides Treatment of CLL: New Drugs on Horizon

January 12th 2012

FISH testing for genetic abnormalities is the key to appropriate treatment selection for patients with CLL.

Progress Made, but More Work Lies Ahead in CLL and CRC Treatment

October 31st 2011

A look at the benefits of the chemoimmunotherapy rituximab for CLL and a look at the treatments and advances made in treating metastatic CRC.